Mechanism of coronary flow reserve reduction in systemic sclerosis: Insight from intracoronary pressure wire studies

Rheumatology

Volumn 50, Issue 4, 2011, Pages 781-788

  Pintér, Tünde ^a   Faludi, Réka ^a   Magyari, Balázs ^a   Vorobcsuk, András ^a   Kumánovics, Gábor ^b   Minier, Tünde ^b   Czirják, László ^b   Komócsi, András ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Autoimmune diseases; Coronary flow reserve; Index of myocardial resistance; Myocardial ischaemia; Systemic sclerosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PENTOXIFYLLINE; SODIUM CHLORIDE;

ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; COLD TREATMENT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY PRESSURE; CORONARY FLOW RESERVE; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPEREMIA; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; VASCULAR RESISTANCE;

ADAPTATION, PHYSIOLOGICAL; AGED; BLOOD PRESSURE; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY VESSELS; ECHOCARDIOGRAPHY; ENDOVASCULAR PROCEDURES; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; SCLERODERMA, SYSTEMIC; VASODILATION;

EID: 79952784034     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq402     Document Type: Article

References (40)

1. Belch JJF, McSwiggan S, Lau C. Macrovascular disease in systemic sclerosis: the tip of an iceberg? Rheumatology 2008;47(Suppl. 5):16-7.
2. Czirjak L, Pakozdi A, Kumanovics G et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2007;67:59-63.
3. Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81:139-53.
4. Ioannidis J, Vlachoyiannopoulos P, Haidich A et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2-10.
5. Komócsi A, Pintér T, Faludi R et al. Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2010;69:202-5.
6. Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008;20:697-702.
7. Gustafsson R, Mannting F, Kazzam E, Waldenström A, Hälgren R. Cold-induced reversible myocardial ischaemia in systemic sclerosis. Lancet 1989;2:475-9.
8. Long A, Duffy G, Bresnihan B. Reversible myocardial perfusion defects during cold challenge in scleroderma. Br J Rheumatol 1986;25:158-61.
9. Simeon C, Armadans L, Fonollosa V et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997;56: 723-8.
10. Vacca A, Siotto P, Cauli A et al. Absence of epicardial coronary stenosis in patients with systemic sclerosis with severe impairment of coronary flow reserve. Ann Rheum Dis 2006;65:274-5.
11. Kahan A, Nitenberg A, Foult J et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 1985;28:637-46.
12. D'Andrea A, Caso P, Cuomo S et al. Myocardial and vascular dysfunction in systemic sclerosis: the potential role of noninvasive assessment in asymptomatic patients. Int J Cardiol 2007;121:298-301.
13. Montisci R, Vacca A, Garau P et al. Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. Ann Rheum Dis 2003;62:890-3.
14. Montisci R, Ruscazio M, Lai S et al. Effect of a single IV administration of L-propionylcarnitine on myocardial microcirculation assessed by coronary flow velocity reserve measurement in patients with systemic sclerosis: a pilot study. Clin Ther 2007;29:163-71.
15. Nitenberg A, Foult J, Kahan A et al. Reduced coronary flow and resistance reserve in primary scleroderma myocardial disease. Am Heart J 1986;112:309-15.
16. Sulli A, Ghio M, Bezante G et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology 2004;43: 505-9.
17. Tarek G, Yasser A, Gheita T. Coronary angiographic findings in asymptomatic systemic sclerosis. Clin Rheumatol 2006;25:487-90.
18. Tzelepis GE, Kelekis NL, Plastiras SC et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007;56:3827-36.
19. Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and tissue-Doppler echography study. J Rheumatol 2006;33:2464-9.
20. Duboc D, Kahan A, Maziere B et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Arthritis Rheum 1991;34:198-203.
21. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology 2006;45(Suppl. 4):14-7.
22. Kahan A, Devaux J, Amor B et al. Nicardipine improves myocardial perfusion in systemic sclerosis. J Rheumatol 1988;15:1395-400.
23. Allanore Y, Meune C, Vonk MC et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218-21.
24. LeRoy E, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
25. McGoon M, Gutterman D, Steen V et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
26. Valgimigli M, Serruys P, Tsuchida K et al. Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007;99: 1072-81.
27. Kahan A, Devaux JY, Amor B et al. Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. Ann Rheum Dis 1986;45:718-25.
28. Nakajima K, Taki J, Kawano M et al. Diastolic dysfunction in patients with systemic sclerosis detected by gated myocardial perfusion SPECT: an early sign of cardiac involvement. J Nucl Med 2001;42:183-8.
29. Stoker ME, Gerdes AM, May JF. Regional differences in capillary density and myocyte size in the normal human heart. Anat Rec 1982;202:187-91.
30. Aarnoudse W, Fearon W, Manoharan G et al. Epicardial stenosis severity does not affect minimal microcirculatory resistance. Circulation 2004;110:2137-42.
31. Fearon W, Aarnoudse W, Pijls N et al. Microvascular resistance is not influenced by epicardial coronary artery stenosis severity: experimental validation. Circulation 2004;109:2269-72.
32. Caiati C, Montaldo C, Zedda N, Bina A, Iliceto S. New noninvasive method for coronary flow reserve assessment: contrast-enhanced transthoracic second harmonic echo Doppler. Circulation 1999;99:771-8.
33. Caiati C, Montaldo C, Zedda N et al. Validation of a new noninvasive method (contrast-enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve: comparison with intracoronary Doppler flow wire. J Am Coll Cardiol 1999;34:1193-200.
34. Andersen GN, Mincheva-Nilsson L, Kazzam E et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 2002;46:1324-32.
35. Akram M, Handler C, Williams M et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology 2006;45:1395-8.
36. Bulkley B, Ridolfi R, Salyer W, Hutchins G. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 1976;53:483-90.
37. Hachulla A, Launay D, Gaxotte V et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878-84.
38. Mukerjee D, Yap LB, Ong V et al. The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Ann Rheum Dis 2004;63:1627-31.
39. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
40. Khanna D, Furst D, Clements P et al. Responsiveness of the SF-36 and the health assessment questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40.